U.S. Markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.77
    -0.51 (-2.50%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.5422%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • Vix

    26.70
    -2.01 (-7.00%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.5930%)
     
  • USD/JPY

    135.1750
    -0.5530 (-0.4074%)
     
  • BTC-USD

    19,271.34
    +8.69 (+0.05%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.38 (-1.73%)
     

Blueprint Medicines (BPMC) Set to Acquire Lengo Therapeutics

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Blueprint Medicines Corporation BPMC announced a definitive agreement to acquire San Diego, CA-based privately held biopharmaceutical company, Lengo Therapeutics, for $250 million in cash. The company will also make up to $215 million as potential payments based on the achievement of certain milestones.

The transaction is expected to close later in the fourth quarter of 2021 and is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Shares of Blueprint Medicines have declined 12.4% so far this year compared with the industry’s decrease of 15.8%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

With the above-mentioned acquisition, Blueprint Medicines is looking to expand its precision oncology therapies and transform treatment for patients with EGFR-driven lung cancer. The acquisition will add Lengo Therapeutics’ lead compound, LNG-451, to Blueprint Medicines’ portfolio.

LNG-451, a potential best-in-class oral precision therapy, is currently being developed for the treatment of non-small cell lung cancer (“NSCLC”) in patients with EGFR exon 20 insertion mutations.

Data from pre-clinical studies have demonstrated that LNG-451 potently inhibits all common EGFR exon 20 insertion variants with marked selectivity over wild-type EGFR and off-target kinases. Also, LNG-451 is highly brain-penetrant and has shown compelling activity in a preclinical intracranial disease model.

Lengo Therapeutics plans to file an investigational new drug application to the FDA to begin clinical studies on LNG-451 in December 2021.

The acquisition of Lengo Therapeutics will also add additional undisclosed preclinical precision oncology programs to Blueprint Medicines’ portfolio for future drug discovery efforts.

Please note that Blueprint Medicines has started a phase I/II SYMPHONY study on BLU-945 – a triple-mutant EGFR inhibitor – to address patients with treatment-resistant EGFR-driven NSCLC. The company also plans to initiate a phase I/II study on BLU-701 for treating patients with EGFR-driven NSCLC later in the fourth quarter of 2021.

Zacks Rank & Stocks to Consider

Blueprint Medicines currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Sarepta Therapeutics, Inc. SRPT, vTv Therapeutics Inc. VTVT and Editas Medicine, Inc. EDIT, all carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Sarepta Therapeutics’ loss per share estimates have narrowed 31.3% for 2021 and 26% for 2022, over the past 60 days.

Earnings of Sarepta Therapeutics have surpassed estimates in two of the trailing four quarters, and missed the same on the other two occasions.

vTv Therapeutics’ loss per share estimates have narrowed 21.7% for 2021 and 2.9% for 2022, over the past 60 days.

vTv Therapeutics’ earnings have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.

Editas Medicine’s loss per share estimates have narrowed 11.2% for 2021 and 4.6% for 2022, over the past 60 days.

Editas Medicine’s earnings have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report

vTv Therapeutics Inc. (VTVT) : Free Stock Analysis Report

Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report

Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research